← All trials
NCT02681640
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2016
- Primary completion
- Feb 10, 2017
- Completion date
- Mar 31, 2017
- First posted
- Feb 12, 2016
- Last posted
- Apr 6, 2017
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenReponsible party - principal investigator
- University of CopenhagenSponsor investigator
- University of CopenhagenOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.